Are there differences in the catalytic activity per unit enzyme of recombinantly expressed and human liver microsomal cytochrome P450 2C9? A systematic investigation into inter-system extrapolation factors-Reference-Cited by-同舟云学术

Are there differences in the catalytic activity per unit enzyme of recombinantly expressed and human liver microsomal cytochrome P450 2C9? A systematic investigation into inter-system extrapolation factors

Published:2011-07-04 Issue:6 Volume:32 Page:303-318
ISSN:0142-2782
Container-title:Biopharmaceutics & Drug Disposition
language:en
Short-container-title:Biopharm. Drug Dispos.

Author:

Crewe H. K.,Barter Z. E.,Rowland Yeo K.¹,Rostami-Hodjegan A.²

Affiliation:

1. Simcyp Ltd; John Street; Sheffield; UK

2. Academic Unit of Clinical Pharmacology; University of Sheffield, Royal Hallamshire Hospital; Sheffield; UK

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science,Pharmacology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/bdd.760/fullpdf

Reference56 articles.

1. The use of heterologously expressed drug metabolizing enzymes - state of the art and prospects for the future;Crespi;Pharmacol Ther,1999

2. Cytochrome P450 reaction-phenotyping: an industrial perspective;Zhang;Expert Opin Drug Metab Toxicol,2007

3. Reaction phenotyping: current industry efforts to identify enzymes responsible for metabolizing drug candidates;Harper;AAPS J,2008

4. Prediction of in vivo drug clearance from in vitro data. I: impact of inter-individual variability;Howgate;Xenobiotica,2006

5. The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer based simulation (SimCYP) predicts in vivo metabolic inhibition;Rakhit;Eur J Clin Pharmacol,2008

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Enzyme-mediated drug-drug interactions: a review of in vivo and in vitro methodologies, regulatory guidance, and translation to the clinic;Drug Metabolism Reviews;2024-07-26

2. Non-additivity of the functional properties of individual P450 species and its manifestation in the effects of alcohol consumption on the metabolism of ketamine and amitriptyline;2024-06-15

3. Application of reaction phenotyping to address pharmacokinetic variability in patient populations;Overcoming Obstacles in Drug Discovery and Development;2023

4. Phase I Metabolism of Pterostilbene, a Dietary Resveratrol Derivative: Metabolite Identification, Species Differences, Isozyme Contribution, and Further Bioactivation;Journal of Agricultural and Food Chemistry;2022-12-20

5. Examining Physiologically Based Pharmacokinetic Model Assumptions for Cross-Tissue Similarity of Activity per Unit of Enzyme: The Case Example of Uridine 5′-Diphosphate Glucuronosyltransferase;Drug Metabolism and Disposition;2022-05-30